Monogenic autoinflammatory diseases

Rheumatology (United Kingdom)

Volumn 53, Issue 11, 2014, Pages 1927-1939

  Russo, Ricardo A G ^a   Brogan, Paul A ^b,c  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Autoinflammatory; Biologic agents; Familial Mediterranean fever; Genetic; Periodic fevers

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CRYOPYRIN; CYSTEINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; JANUS KINASE INHIBITOR; NUCLEAR FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SIMVASTATIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CINCA SYNDROME; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; EARLY ONSET SARCOIDOSIS; FAMILIAL MEDITERRANEAN FEVER; FIBROUS DYSPLASIA; GENE MUTATION; GUADELOUPE TYPE FEVER SYNDROME; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INNATE IMMUNITY; INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; MAJEED SYNDROME; MEVALONATE KINASE DEFICIENCY; MONOGENIC AUTOINFLAMMATORY DISEASE; NALP12 ASSOCIATED PERIODIC SYNDROME; PAPA SYNDROME; PFAPA SYNDROME; PROTEIN FOLDING; RECURRENT FEVER; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 84911481744     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu170     Document Type: Review

References (165)

1. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010;140:784-90.
2. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90: 797-807.
3. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.
4. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.
5. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27: 621-8.
6. McGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and immunological disease continuum. Pediatr Res 2009;65: 38-45R.
7. Lachmann HJ, Hawkins PN. Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther 2009;11:212.
8. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:227-53.
9. Samuels J, Aksentijevich I, Torosyan Y et al. Familial Mediterranean fever at the millennium: clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 1998;77: 268-97.
10. Tunca M, Akar S, Onen F et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005;84:1-11.
11. Ozdogan H, Arisoy N, Kasapçapur O et al. Vasculitis in familial Mediterranean fever. J Rheumatol 1997;24:323-7.
12. Padeh S, Livneh A, Pras E et al. Familial Mediterranean fever in the first two years of life: a unique phenotype of disease in evolution. J Pediatr 2010;156:985-9.
13. Booty MG, Chae JJ, Masters SL et al. Familial Mediterranean Fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009;60:1851-61.
14. Marek-Yagel D, Berkun Y, Padeh S et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 2009;60:1862-6.
15. Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85.
16. Gershoni-Baruch R, Brik R, Zacks N et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003;48:1149-55.
17. Touitou I, Sarkisian T, Medlej-Hashim M et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56: 1706-12.
18. Williamson LM, Hull D, Mehta R et al. Familial Hibernian fever. Q J Med 1982;51:469-80.
19. Hull KM, Drew E, Aksentijevich I et al. The TNF receptorassociated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 2002; 81:349-68.
20. Aganna E, Hammond L, Hawkins PN et al. Heterogeneity among patients with tumor necrosis factor receptorassociated periodic syndrome phenotypes. Arthritis Rheum 2003;48:2632-44.
21. Ravet N, Rouaghe S, Dodé C et al. Clinical significance of P46L and R92Q substitutions in the tumor necrosis factor superfamily 1A gene. Ann Rheum Dis 2006;65:1158-62.
22. Lachmann HJ, Papa R, Gerhold K et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases form the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2013, Aug 21. doi: 10.1136/annrheumdis-2013- [Epub ahead of print].
23. Pelagatti MA, Meini A, Caorsi R et al. Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 2011;63:1141-50.
24. Drenth JPH, Haagsma CJ, van der Meer JWM. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. Medicine 1994;73:133-44.
25. Drenth JP, Cuisset L, Grateau G et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999;22:178-81.
26. Houten SM, Kuis W, Duran M et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999; 22:175-7.
27. Mandey SH, Schneiders MS, Koster J, Waterham HR. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006; 27:796-802.
28. Samkari A, Borzutzky A, Fermo E et al. A novel missense mutation in MVK associated with MK deficiency and dyserythropoietic anemia. Pediatrics 2010;125:e964-8.
29. Frenkel J, Houten SM, Waterham HR et al. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology 2001;40: 579-84.
30. van der Hilst JC, Bodar EJ, Barron KS et al. Long term follow-up, clinical features and quality of life in a series of patients with hyperimmunoglobulinemia D syndrome. Medicine 2008;87:301-10.
31. Bader-Meunier B, Florkin B, Sibilia J et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 2011; 128:e152-9.
32. Saulsbury FT. Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) in a child with normal serum IgD, but increased serum IgA concentration. J Pediatr 2003; 143:127-9.
33. Ammouri W, Cuisset L, Rouaghe S et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology 2007;46:1597-600.
34. Lachmann HJ, Goodman HJB, Andrews PA et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome. A report of two cases. Arthritis Rheum 2006;54:2010-4.
35. Sornsakrin M, Wenner K, Ganschow R. B cell cytopenia in two brothers with hyper-IgD and periodic fever syndrome. Eur J Pediatr 2009;168:825-31.
36. Rigante D, Capoluongo E, Bertoni B et al. First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2007;56:658-81.
37. Muckle TJ, Wells M. Urticaria, deafness and amyloidosis: a new heredo-familial syndrome. Q J Med 1962;31: 235-48.
38. Prieur AM, Griscelli C. Arthropathy with rash, chronic meningitis, eye lesions, and mental retardation. J Pediatr 1981;99:79-83.
39. Aksentijevich I, Putnam D, Remmers EF et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-85.
40. Hentgen V, Despert V, Lepretre AC et al. Intrafamilial variable phenotypic expression of a CIAS1 from Muckle- Wells to chronic infantile neurological cutaneous and articular syndrome. J Rheumatol 2005;32:747-51.
41. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-5.
42. Feldmann J, Prieur AM, Quartier P et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203.
43. Aksentijevich I, Nowak M, Mallah M et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8.
44. Aróstegui JI, Aldea A, Modesto C et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/ PYPAF1/NALP3 gene. Arthritis Rheum 2004;50:4045-50.
45. Aróstegui JI, Lopez Saldaña MD, Pascal M et al. A somatic NLRP3 mutation as a cause of sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal- onset multisystem inflammatory disease. Arthritis Rheum 2010;62:1158-66.
46. Tanaka N, Izawa K, Saito MK et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurological, cutaneous, articular syndrome. Arthritis Rheum 2011;63:3625-32.
47. Omoyinmi E, Melo Gomes S, Standing S et al. Whole exome sequencing revealing somatic NLRP3 mosaicism in a patient with chronic infantile neurological cutaneous and articular syndrome. Arthritis Rheum 2014;66:197-202.
48. Prieur AM, Griscelli C, Lampert F et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57-68.
49. Aganna E, Martinon F, Hawkins PN et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002;46:2445-52.
50. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum and acne: PAPA syndrome. Mayo Clin Proc 1997;72:611-5.
51. Wise CA, Gilium JD, Seidman CE et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961-9.
52. Demidowich AP, Freeman AF, Kuhns DB et al. Genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012;64:2022-7.
53. Marzano AV, Trevisan V, Gattorno M et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis supurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013;149:762-4.
54. Aksentijevich I, Masters SL, Ferguson PJ et al. An autoinflammatory disease with deficiency of the interleukin-1- receptor antagonist. N Engl J Med 2009;360:2426-37.
55. Reddy S, Jia S, Geoffrey R et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009;360:2438-44.
56. Jesus AA, Osman M, Silva CS et al. A novel mutation of ILRN in the deficiency of interleukin-1 receptor antagonist syndrome. Description of two unrelated cases from Brazil. Arthritis Rheum 2011;63:4007-17.
57. Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36- receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365:620-8.
58. Rosé CD, Aróstegui JI, Martin TM et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype. Study of an international registry and a national cohort in Spain. Arthritis Rheum 2009;60:1797-803.
59. Miceli-Richard C, Lesage S, Rybojad M et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19-20.
60. Kanazawa N, Okafuji I, Lambe N et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kB activation: common genetic etiology with Blau syndrome. Blood 2005;105:1195-7.
61. Rosé CD, Doyle TM, McIlvain-Simpson G et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005;32:373-5.
62. Borghini S, Tassi S, Chiesa S et al. Clinical presentation and pathogenesis of cold induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011;63:830-9.
63. Jéru I, Duquesnoy P, Fernandes-Alnemri T et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 2008;105:1614-9.
64. Ferguson PJ, El-Shanti HI. Autoinflammatory bone disorders. Curr Opin Rheumatol 2007;19:492-8.
65. Majeed HA, Kalaawi M, Mohanty D et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr 1989;115: 730-4.
66. Ferguson PJ, Chen S, Tayeh MK et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia (Majeed syndrome). J Med Genet 2005;42:551-7.
67. Al-Mosawi ZS, Al-Saad KK, Ijadi-Maghsoodi R et al. A splice site mutation confirms the role of LPIN2 in Majeed syndrome. Arthritis Rheum 2007;56:960-4.
68. Liu Y, Ramot Y, Torrelo A et al. Mutations in preoteasome subunit b type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012;64:895-907.
69. Agarwal AK, Xing C, DeMartino G et al. PSMB8 encoding the b5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis- induced lipodystrophy syndrome. Am J Human Genet 2010;87:866-72.
70. Arima K, Kinoshita A, Mishima H et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA 2011;108:14914-9.
71. Standing A, Omoyinmi E, Brogan P. Gene hunting in autoinflammation. Clin Transl Allergy 2013;3:32.
72. Toiutou I, Galeotti C, Rossi-Semerano S et al. The expanding spectrum of rare monogenic autoinflammatory diseases. Orphanet J Rare Dis 2013;8:162.
73. Omenetti A, Federici S, Gattorno M. Inherited autoinflammatory diseases: a critical digest of the recent literature. Clin Exp Rheumatol 2013;31(Suppl 77):S118-26.
74. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2014;10:135-47.
75. Jordan CT, Cao L, Roberson EDO et al. PSORS2 is due to mutations in CARD 14. Am J Hum Genet 2012;90: 784-95.
76. Ombrello M, Remmers EF, Sun G et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012;366:330-8.
77. Zhou Q, Lee GS, Brady J et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cg2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 2012;91:713-20.
78. Boisson B, Laplantine E, Prando C et al. Immunodeficiency, auto-inflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012;13:1178-86.
79. Melki I, Lambot K, Jonard L et al. Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition. Pediatrics 2013;131:e1308.
80. Senniappan S, Hughes M, Shah P et al. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome. J Pediatr Endocrinol Metab 2013;26:1-6.
81. Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45.
82. Kotlarz D, Beier R, Murugan D et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143:347-55.
83. Park H, Bourla AB, Kastner DL et al. Lighting the fire within: the cell biology of autoinflammatory diseases. Nat Rev 2012;570-80.
84. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1. Mol Cell 2002;10: 417-26.
85. Agostini L, Martinon F, Burns K et al. NALP3 forms an IL-1- processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-25.
86. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007;7:31-40.
87. Shoham NG, Centola M, Mansfield E et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003;100:13501-6.
88. Dinarello CA. Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1b secretion and disease activity. Arthritis Rheum 2007;56: 2817-22.
89. Mandey SH, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006;54:3690-5.
90. Pontillo A, Paoluzzi E, Crovella S. The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 2010;18:844-7.
91. Jéru I, Hentgen V, Normand S et al. Role of interleukin- 1beta in NLRP12-associated autoinflammatory disorders and resistance to antiinterleukin-1 therapy. Arthritis Rheum 2011;63:2142-8.
92. Martin TM, Zhang Z, Kurz P et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009;60:611-8.
93. Huggins ML, Radford PM, McIntosh RS et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 2004;50:2651-9.
94. D'Osualdo A, Ferlito F, Prigione I et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006;54: 998-1008.
95. Lobito AA, Kimberley FC, Muppidi JR et al. Abnormal disulfide- linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006;108: 1320-7.
96. Bulua AC, Simon A, Maddipati R et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011;208: 519-33.
97. Mitroulis I, Kourtzelis I, Kambas K et al. Evidence for the involvement of mTOR inhibition and basal autophagy in familial Mediterranean fever phenotype. Hum Immunol 2011;72:135-8.
98. van der Burgh R, Nijhuis L, Pervolaraki K et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1b hypersecretion. J Biol Chem 2014;289: 5000-12.
99. Yalçinkaya F, Özen S, Ösçakar ZB et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology 2009;48:395-8.
100. Kondi A, Hentgen V, Piram M et al. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of children from the French reference centre for autoinflammatory disorders. Rheumatology 2010;49:2200-3.
101. Federici I, Rittore-Domingo C, KonéPaut I et al. A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis 2006;65: 1427-32.
102. Gattorno M, Sormani MP, D'Osualdo A et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008;58:1823-32.
103. Gattorno M, Caorsi R, Meini A et al. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009;124:e721-8.
104. Simon A, van der Meer JW, Vesely R et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology 2006;45:269-73.
105. Shinar Y, Obici L, Aksentijevich I et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012;71:1599-605.
106. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature. J Med Genet 2013;50:349-59.
107. Koné-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I. Autoinflammatory gene mutations in Behçet's disease. Ann Rheum Dis 2007;66:832-4.
108. Berkun Y, Levy R, Hurwitz A et al. The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum 2011;40:467-72.
109. Ozen S, Bakkaloglu A, Yilmaz E et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003;30:2014-8.
110. Marek-Yagel D, Berkun Y, Padeh S et al. Role of the R92Q TNFRSF1A mutation in patients with familial Mediterranean fever. Arthritis Care Res 2010;62:1294-8.
111. Stojanov S, Lohse P, Lohse P et al. Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004;50: 1951-8.
112. Toplak N, Frenkel J, Ozen S et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012;71:1177-82.
113. De Menthiere CS, Terriere S, Pugnere D et al. INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003;31:282-5.
114. Lainka E, Bielak M, Hilger V et al. Translational research network and patient registry for auto-inflammatory diseases. Rheumatology 2011;50:237-42.
115. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever: a controlled, double-blind study. Ann Intern Med 1974;81:792-4.
116. Zemer D, Revach M, Pras M et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974;291:932-4.
117. Dinarello CA, Wolff SM, Goldfinger SE et al. Colchicine therapy for familial Mediterranean fever. A double-blind trial. N Engl J Med 1974;291:934-7.
118. Kallinich T, Haffner D, Niehues T et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119:e474-83.
119. Ter Haar N, Lachmann H, Özen S et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72: 678-85.
120. Simon A, Drewe E, van der Meer JW et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476-83.
121. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin- 1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4.
122. Hoffman HM, Rosengren S, Boyle DL et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85.
123. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50: 607-12.
124. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1b inhibition. N Engl J Med 2006; 355:581-92.
125. Metyas SK, Hoffman HM. Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease. J Rheumatol 2006;33:2085-7.
126. Leslie KS, Lachmann HJ, Bruning E et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142: 1591-7.
127. Neven B, Marvillet I, Terrada C et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurological, cutaneous, articular syndrome. Arthritis Rheum 2010;62:258-67.
128. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011;63:840-9.
129. Sibley CH, Plass N, Snow J et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease (NOMID) treated with anakinra. Arthritis Rheum 2012;64: 2375-86.
130. Alten R, Gram H, Joosten LA et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R67.
131. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
132. Kuemmerle-Deschner JB, Ramos E, Blank N et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1b mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011;13:R34.
133. Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70:2095-102.
134. Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrinassociated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13: R202.
135. Kuemmerle-Deschner JB, Lohse P, Koetter I et al. NLRP3 E311K mutation in a large family with Muckle- Wells syndrome-description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther 2011;13:R196.
136. Caorsi R, Lepore L, Zulian F et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013; 15:R33.
137. Imagawa T, Nishikomori R, Takada H et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013;31: 302-9.
138. Russo RA, Melo-Gomes S, Lachmann HJ et al. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a singlecentre, real world experience. Rheumatology 2014;53: 665-70.
139. Goldbach-Mansky R, Shroff SD, Wilson M et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58: 2432-42.
140. Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
141. Simon A, Bodar EJ, van der Hilst JC et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med 2004;117:208-10.
142. Gattorno M, Pelagatti MA, Meini A et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008;58:1516-20.
143. Obici L, Meini A, Cattalini M et al. Favourable and sustained response to anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011;70: 1511-2.
144. Bodar EJ, Kuijk LM, Drenth JP et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 2011;70:2155-8.
145. Galeotti C, Meinzer U, Quartier P et al. Efficacy of interleukin- 1-targeting drugs in mevalonate kinase deficiency. Rheumatology 2012;51:1855-9.
146. Ozen S, Bilginer Y, Aktay Ayaz N et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011;38:516-8.
147. Meinzer U, Quartier P, Alexandra JF et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011;41:265-71.
148. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005;44:406-8.
149. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2006;161: 1199-201.
150. Aróstegui JI, Arnal C, Merino R et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007;56:3805-13.
151. Simonini G, Xu Z, Caputo R et al. Clinical and transcriptional response to the long-acting Interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 2013;65:513-8.
152. Drewe E, McDermott EM, Powell PT et al. Prospective study of anti-tumor necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumor necrosis factor receptor superfamily 1A fusion protein, in tumor necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 2003;42:235-9.
153. Nowlan ML, Drewe E, Bulsara H et al. Systemic cytokine levels and the effects of etanercept in TNF receptorassociated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology 2006;45:31-7.
154. Stojanov S, Dejaco C, Lohse P et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/ V173D cleavage site mutation associated with tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008;67:1292-8.
155. Bulua AC, Mogul DB, Aksentijevich I et al. Efficacy of etanercept in the tumor necrosis factor receptorassociated periodic syndrome: a prospective, openlabel, dose-escalation study. Arthritis Rheum 2012;64: 908-13.
156. Arkwright PD, McDermott MF, Houten SM et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002;130:484-8.
157. Takada K, Aksentijevich I, Mahadevan V et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
158. Bilgen SA, Kilic L, Akdogan A et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 2011; 17:358-62.
159. Cortis E, De Benedetti F, Insalaco A et al. Abnormal production of the tumor necrosis factor and clinical efficacy of the tumor necrosis factor inhibitor etanercept in a patient with PAPA syndrome. J Pediatr 2004;145: 851-5.
160. Vaitla PM, Radford PM, Tighe PJ et al. Role of interleukin- in a patient with tumor necrosis factor receptorassociated periodic syndrome: assessment of outcomes following treatment with the antiinterleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63:1151-5.
161. Tunca M, Tankurt E, Akbaylar Akpinar H et al. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997;36:1005-8.
162. Tweezer-Zaks N, Rabinovich E, Lidar M et al. Interferonalpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J Rheumatol 2008;35: 1362-5.
163. Tunca M, Akar S, Soytürk M et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004;22(Suppl 34):S37-40.
164. Calguneri M, Apras S, Ozbalkan Z et al. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22(Suppl 34):S41-4.
165. NIH Clinical Center. Compassionate Use Treatment Protocol I4V-MC-JAGA; Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK Inhibition. http://clinicalstudies.info.nih.gov/cgi/detail.cgi? A_2012-AR-8001.html (20 October 2013, date last accessed).